<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542356</url>
  </required_header>
  <id_info>
    <org_study_id>CQGOG0104</org_study_id>
    <nct_id>NCT04542356</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer</brief_title>
  <official_title>Efficacy and Safety of PEGylated Recombinant Human Granulocyte Stimulating Factor in the Prevention of Neutropenia During Concurrent Chemoradiotherapy for Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing University Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled prospective study aims to explore the efficacy and safety of using&#xD;
      (PEGylated Recombinant Human Granulocyte Stimulating Factor) PEG-rhG-CSF to prevent&#xD;
      neutropenia during concurrent chemoradiotherapy of paclitaxel and cisplatin (TP) regimen for&#xD;
      cervical cancer. To find out the best time to use PEG-rhG CSF, and to explore investigate the&#xD;
      effect of PEG-rhG-CSF on long-term bone marrow function in the process of concurrent&#xD;
      chemoradiotherapy, and finally to explore the clinical feasibility of using PEG-rhG-CSF to&#xD;
      prevent neutropenia during concurrent chemoradiotherapy of TP regimen for cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: In this prospective, single-center, randomized controlled study, patients with&#xD;
      locally advanced cervical cancer are randomly divided into two groups. Patients in the&#xD;
      experimental group will receive PEG-rhG-CSF 6mg prevention during concurrent&#xD;
      chemoradiotherapy, whereas the control group do not use PEG-rhG-CSF for prevention. When the&#xD;
      patient's ANC is less than 1✕109/L, 5μg/kg rhG-CSF will be given for treatment until the ANC&#xD;
      returned to 2✕109/L.&#xD;
&#xD;
      Case selection: patients with IIb-IIIb cervical cancer, squamous cell carcinoma confirmed by&#xD;
      histopathology, and three-week regimen of paclitaxel and carboplatin with Concurrent&#xD;
      Radiotherapy.&#xD;
&#xD;
      Primary end point: incidence and duration of grade 3/4 neutropenia in patients. Secondary&#xD;
      endpoints: 1) Incidence of febrile neutropenia (FN); 2) the rate of postponement of the&#xD;
      course of radiotherapy, reduction in chemotherapy dose and postponement of the course of&#xD;
      chemotherapy; 3) Changes of bone marrow function in patients 3 months and 6 months after&#xD;
      radiotherapy.&#xD;
&#xD;
      Safety assessment: laboratory safety testing, including platelet count and hemoglobin.&#xD;
      Evaluation of adverse events: infection, neutropenic fever, bone pain, etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">May 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 3-4 neutropenia</measure>
    <time_frame>2 months</time_frame>
    <description>Incidence of Grade 3-4 neutropenia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of grade 3-4 neutropenia</measure>
    <time_frame>2 months</time_frame>
    <description>Duration of grade 3-4 neutropenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia (FN)</measure>
    <time_frame>2 months</time_frame>
    <description>Incidence of febrile neutropenia (FN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of postponement of the course of radiotherapy</measure>
    <time_frame>2 months</time_frame>
    <description>the rate of postponement of the course of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction in chemotherapy dose</measure>
    <time_frame>2 months</time_frame>
    <description>reduction in chemotherapy dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postponement of the course of chemotherapy</measure>
    <time_frame>2 months</time_frame>
    <description>postponement of the course of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of bone marrow function in patients 3 months and 6 months after radiotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>Changes of bone marrow function in patients 3 months and 6 months after radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC&lt;1✕109/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1）18-70 years old; 2）Patients with cervical cancer who have not undergone surgery for&#xD;
        initial treatment, the international union of gynecology and obstetrics (FIGO) stage&#xD;
        IIb-IIIb; Squamous cell carcinoma diagnosed by histopathology.&#xD;
&#xD;
        3）The expected survival time was more than 8 months; the Eastern Cooperative Oncology Group&#xD;
        (ECOG) performance status score≤1; 4）Bone marrow hematopoietic function is normal before&#xD;
        treatment (ANC≥1.8×109/L, PLT≥100×109/L, Hb≥90g/L, WBC≥4.0×109/L); 5）No obvious abnormality&#xD;
        in the ECG examination, and no obvious cardiac dysfunction; 6）All patients must agree to&#xD;
        take effective contraceptive measures during the study period and within 6 months after&#xD;
        stopping treatment, and women of childbearing age must have a negative urine pregnancy test&#xD;
        prior to treatment administration; 7）The subjects voluntarily participate in this clinical&#xD;
        trial and sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1）Those who refuse to accept PEG-rh-G-CSF; 2) Currently conducting clinical trials of other&#xD;
        drugs; 3) Uncontrolled infection before treatment, body temperature ≥ 38℃; 4）Chronic&#xD;
        diseases of the heart, kidney, liver or other important organs; 5) Patients with severe&#xD;
        uncontrolled diabetes; (6) Pregnant or lactating female patients; 7）Persons with allergic&#xD;
        diseases or allergic constitution, or allergic to this product or other biological products&#xD;
        derived from genetically engineered E. coli; 8) Suspected or confirmed drug, substance or&#xD;
        alcohol abuse; 9) Severe mental or neurological disorders that affect informed consent&#xD;
        and/or adverse reaction presentation or observation; 10）HIV-positive people; 11）Patients&#xD;
        requiring radiation therapy for the retroperitoneal or inguinal region.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongling Zou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing University Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cartmell MP, Ziegler SW, Neill DS. On the performance prediction and scale modelling of a motorised momentum exchange propulsion tether[J]. Gynecol Oncol, 2003, 654 (1): 571-579.</citation>
  </reference>
  <reference>
    <citation>Liu Y, Zhang X, An S, Wu Y, Hu G, Wu Y. Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo. Cancer Chemother Pharmacol. 2015 Mar;75(3):465-74. doi: 10.1007/s00280-014-2658-7. Epub 2015 Jan 1.</citation>
    <PMID>25552400</PMID>
  </reference>
  <reference>
    <citation>Saha A, Chaudhury AN, Bhowmik P, Chatterjee R. Awareness of cervical cancer among female students of premier colleges in Kolkata, India. Asian Pac J Cancer Prev. 2010;11(4):1085-90.</citation>
    <PMID>21133629</PMID>
  </reference>
  <reference>
    <citation>Moore TD，Patel T，et al．A sir pesfligrastim dose per cycle supports dose-dense(q14d)CHOP-R in patients with non Hodgkin's lymphoma[J]．Proc Am Soc Hematol，2003，102(11): 2365．</citation>
  </reference>
  <reference>
    <citation>Lokich J. Same-day pegfilgrastim and chemotherapy. Cancer Invest. 2005;23(7):573-6.</citation>
    <PMID>16305982</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing University Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Dongling Zou</investigator_full_name>
    <investigator_title>Associated Director</investigator_title>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <keyword>neutropenia</keyword>
  <keyword>PEG-rhG-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

